Yes...at the last Roth Conference, Shameze the CFO, specifically stated partnership/licensing agreement discussions on their next 3 ANDA's ongoing...but IPCI's been basically playing hardball knowing they either get the full added value price they're now demanding...or they can just as easily do full value development themselves from all the monies from their recent Roth raise and then license all their next pending ANDA's out for full commercialization for even more lucrative returns!!!
So definitely a ton of value prep'n to be unleashed here either way on their next value-driven developments/results k!
The FDA date of acceptance is perhaps the best date to track unless there is a lawsuit then I think the settlement date is better as we've seen with the Focalin approval of 44 months since settlement(s).
Effexor, imo, is making the point for me as it's hitting it's 47 month next week since acceptance but significantly less after the lawsuit settlement date. We'll be lucky if we see something this year. Seroquel will be even further out, imo.
Our focus should be on Glucophage and Protonix as there weren't any lawsuits associated. The timeline should start upon the FDA accepted date which is October 2010 for both so therefore we're hitting the 42nd month for both this month.
Should the extra FDA help not filter down to the generic drugs already in the system and utilizing the 44 month Focalin approval as our only example, I'm looking at June for these (2) myself but I won't be upset if it's quicker,lol.
News 
Market Data 
Discover 
AI
